Method for generation and ex vivo expansion of genetically edited mouse Tregs

Regulatory T cells (Tregs) play a crucial role in the immune system, and their dysfunction can lead to the development of autoimmune conditions. In cancer, tumors frequently hijack the immunosuppressive function of Tregs to evade immune responses. Due to their central role in key pathological processes, Tregs have gained increasing attention as promising targets for various clinical applications. However, their relative scarcity (∼5% to 10% of CD4+ T cells) and instability presents a technical challenge for research and therapeutic development. In congenic animal models used to investigate autologous cell transfer-based therapies, this challenge is even greater, as Treg donor animals may only be able to provide cells to a small number of recipient mice. Here, we present an optimized protocol for ex vivo editing and expansion of mouse Tregs. Because a recent study demonstrated the anticancer potential of SRC-3 KO mouse Tregs, we use them here as a case study.

Authors

Institutions

Publication Details

Journal
Journal of Leukocyte Biology
Published
2025-11-06
DOI
https://doi.org/10.1093/jleuko/qiaf160
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Method for generation and ex vivo expansion of genetically edited mouse Tregs

Adam Dean, Bert W. O’Malley, Yosef Gilad, David M. Lonard et al.
Journal of Leukocyte Biology
CAR-T cell therapy research
article

Method for generation and ex vivo expansion of genetically edited mouse Tregs

Adam Dean, Bert W. O’Malley, Yosef Gilad, David M. Lonard, Sang Jun Han
article en

Abstract

Regulatory T cells (Tregs) play a crucial role in the immune system, and their dysfunction can lead to the development of autoimmune conditions. In cancer, tumors frequently hijack the immunosuppressive function of Tregs to evade immune responses. Due to their central role in key pathological processes, Tregs have gained increasing attention as promising targets for various clinical applications. However, their relative scarcity (∼5% to 10% of CD4+ T cells) and instability presents a technical challenge for research and therapeutic development. In congenic animal models used to investigate autologous cell transfer-based therapies, this challenge is even greater, as Treg donor animals may only be able to provide cells to a small number of recipient mice. Here, we present an optimized protocol for ex vivo editing and expansion of mouse Tregs. Because a recent study demonstrated the anticancer potential of SRC-3 KO mouse Tregs, we use them here as a case study.

Journal of Leukocyte BiologyVol. 117(12)
Baylor College of Medicine (US), Children's Cancer Center (US)
Openalex Percentile: Top 54%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Method for generation and ex vivo expansion of genetically edited mouse Tregs — Adam Dean, Bert W. O’Malley, et al. · Journal of Leukocyte Biology (2025) | TGRS Research Map | TGRS